Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW
Japan on March 5 announced new NHI prices for listed medicines, effective April 1, revealing a 37.3% slash for Novartis Pharma’s Xolair (omalizumab) after its label expansion into pollen allergy, and a further 20.9% reduction for MSD’s fast-growing blockbuster Keytruda…
To read the full story
Related Article
- Novartis Says Only 3,000 Pollen Allergy Patients Used Xolair This Season, Less than 10% of Re-Pricing Line
May 10, 2021
- 7 Generic API Specifications Subject to New Rule to Address Unreasonable Price Rises
March 6, 2020
- 3 Drugs Earn Post-Launch “True Clinical Utility” Premium; Forxiga Price Flat, Rises for Canaglu and Praluent
March 5, 2020
- Price Maintenance Premium Granted to 335 APIs/555 Products; Novartis Top PMP Earner
March 5, 2020
- With 80%-Plus Gx Rates, Many One-Time Blockbusters Might Be In for Earlier “G1” Price Cuts
March 5, 2020
- Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
- Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing
January 23, 2020
- Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana
January 22, 2020
- Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash
January 21, 2020
- Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist
January 20, 2020
REGULATORY
- US Narrows Scope of Medicare MFN Model, Exempts Orphan-Only Drugs
October 2, 2026
- Japan to Draw Up Growth Strategy Action Plan by Year-End
October 2, 2026
- Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
October 1, 2026
- Repatha Optimal Use Guidelines to Be Simplified
October 1, 2026
- Label Revisions Ordered for Checkpoint Inhibitors over Gastritis, Esophagitis
September 30, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…